DURHAMPurdue Pharma is downsizing in the Triangle.

In a company email to employees on Friday, the firm’s CEO Craig Landau announced the drug manufacturer has sold its Treyburn plant in Durham to Novo Nordisk.

He declined to disclose the financial details at this time.

“Given the market dynamics and expected demand for our current portfolio of marketed products, the continued operation of Treyburn can no longer be justified,” Landau wrote in the email obtained by WRAL TechWire.

It is unclear how many jobs will be affected.

Connecticut-based Purdue, which makes pain products such as OxyContin and Butrans, opened the facility in 2015. Estimated to have cost around $59 million, it was created as a backup and overflow to its Wilson facility, employing more than 100 employees.

However, it’s no longer needed, according to the ketter,.

“A thorough analysis of Purdue’s current and future business requirements shows that with additional staffing and the continued leadership of personnel already in place, our Wilson facility is in a position to meet today’s product requirements,” Landau said.

A source told WRAL TechWire that the company has reportedly organized a company meeting for Monday morning, followed by one-on-one sessions with impacted employees at the Durham facility.

It is believed that many are expected to be retained and work at Wilson facility, while others may be offered jobs at Novo Nordisk.

Following the close of purchase, Landau said Perdue plans to lease back the space from Novo Nordisk and occupy it through the fall. The firm plans to vacate the facility on Dec. 1.

“Until that time, we will be operating in a ‘business as usual’ manner,” he said.

Here’s the full letter from CEO Craig Landau.

Purdue Pharma to invest $59M in new Durham manufacturing plant creating 100 jobs